Modern Drug Discovery Challenges Demand a New Pharma Paradigm

Core drug discovery challenges persist despite rapid advances in artificial intelligence, advanced biology, and data science. For the biopharmaceutical industry, the challenge is no longer a lack of innovation but how to determine what will actually speed up and improve drug discovery and development.

Image

Why Drug Discovery Is Still So Difficult

Drug discovery and development is an uphill climb. High attrition rates, uncertainty moving from the lab to the clinic, and fragmented operations still block progress.

Sure, target identification and molecular design have advanced, but the number of winners at the early clinical stage hasn’t kept up, reflecting a translational gap between promising preclinical results and success in clinical trials.

Part of this is the actual science and technology. Plainly, our models aren’t as predictive as we’d like, disease biology is messier than anyone likes to admit, and patient-to-patient drug response varies significantly.

On top of that, drug discovery platforms just keep getting more complicated. Data is scattered and experimental and computational workflows don’t always fit together smoothly. Working with external partners adds another layer of trouble.

The drug discovery tools have gotten faster and smarter, but the system they exist in hasn’t caught up. That’s why progress often feels stuck.

From traditional pipelines to a modern drug discovery paradigm

Traditional drug discovery is complex, time-consuming, and largely sequential. As a result, it’s now being replaced with something a lot more adaptive, which is data-intensive, algorithm-driven, and continuously evolving.

One of the main drivers is that our understanding of biological complexity is now outpacing the traditional linear model of drug discovery.

Disease processes are not single pathways but involve complex network interactions that require genomics, proteomics, metabolomics, microbiome interactions, epigenetics, and pharmacogenetics to be understood properly. 

A linear drug discovery approach cannot effectively model multi-dimensional biology. The industry needs a drug discovery process built for complexity.

Towards a New Pharma Paradigm

The modern pharma paradigm represents a structural redesign that changes how pharmaceutical knowledge is generated, refined, and used.

Where the traditional drug discovery model moved drug candidates through a fixed sequence of discrete stages, each largely isolated from the others, the modern paradigm replaces that architecture with a continuously learning, closed-loop system in which every stage informs the previous ones.

This is the basis of what is often referred to as the “discovery loop”: a Design–Make–Test–Analyse (DMTA) cycle in which computational prediction, automated synthesis, high-throughput biological screening, and AI-driven data interpretation operate not as sequential hands-off steps but as collaborative, mutually reinforcing processes, building on each other’s results in real time. 

In this model, a failed experiment is not a dead end. It's another useful data point that recalibrates the next iteration. The model gets better, and the odds of success improve.

Image

Commercial realities and the cost of failure

Pharma companies must reduce failure earlier and increase the probability of success before expensive clinical trials begin.

A Phase I trial alone costs tens of millions of dollars and typically takes years to complete. A Phase III failure, by far the most catastrophic outcome in drug development, can write off anywhere upward of $100 million in committed capital and set back a therapeutic area by a decade.

With success in Phase I clinical trials stalled at 63 to 70%, and only 30 to 40% in Phase II trials, failure has become structurally unsustainable for most organisations.

The industry has long pushed the mantra of “fail early, fail fast” as the right strategy. But, in reality, that’s proven tough to pull off. Organisations that applied the principle primarily by compressing preclinical timelines or by screening additional compounds earlier found that they were generating more Phase I entries but not materially better drug candidates.

Failing faster is only economically valuable if the quality of the scientific and business decision has genuinely improved; i.e., if the compounds being eliminated were truly non-viable and if the ones advancing have been selected on a more rigorous, multi-dimensional evidence basis.

The modern drug discovery paradigm fixes this by adding a set of mechanisms that meaningfully increase the predictive depth of preclinical decisions, not merely their speed.

These include:

• In silico ADMET profiling that filters out pharmacokinetically compromised compounds before synthesis;
• AI-enabled target validation that assesses causal disease relevance rather than biochemical binding affinity alone;
• Patient-stratification models that identify which patient populations are most likely to respond; and
• Early biomarker programmes that provide mechanistic proof-of-concept signals in Phase I, making later stages less risky.

All of these capabilities are designed to answer the one key question that traditional drug discovery consistently failed to answer early enough: Will this work in the patients who need it?

For organisations willing to invest in detection capability at earlier and earlier stages, including before conventional preclinical testing begins, the competitive advantage is substantial.

Identifying non-viable programmes prior to IND filing not only avoids direct expenditure but also the strategic cost of clinical capacity consumed by low-probability candidates, funding competition for resources that might be allocated to higher-confidence programmes, and the organisational momentum that accrues around drug candidates once human trials begin.

The Hype vs Reality of AI in Drug Discovery

From target identification to lead optimisation, artificial intelligence in drug discovery is now a functional component. It reduces time-to-discovery, improves hit rates, and uncovers biological insights that would be difficult to identify through traditional methods.

However, there are very real challenges in translating computational outputs into clinically-viable drug candidates despite rapid advancement of AI-driven drug discovery approaches.

The AI models used for drug discovery are only as reliable as the data they are trained on. That data is often:

• Incomplete
• Biased toward successful experiments
• Fragmented across organisations

While AI can generate candidate molecules rapidly, it does not eliminate the requirement for experimental validation, and wet-lab testing remains essential.

View interview AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.

Image

The Focus on Next-Generation Modalities

The biopharmaceutical sector is evolving and is now venturing past small molecules and antibody drug conjugates. The industry is gaining ground in a new area of therapies, including gene editing, cell therapies, and mRNA-based treatments.

These emerging modalities hold promise for tackling the high unmet need in areas such as rare diseases.

While scientific advancements in next-gen modalities continue, with more refined targeting and better delivery techniques, these innovations are not without their hurdles.

The regulations for next-gen modalities are still unclear and draft guidances are incomplete and opaque. This is particularly true for the “flexible” U.S. Food and Drug Administration (FDA) cell and gene therapy requirements and European Medicines Agency (EMA) requirements regarding advanced medicinal products.

Operationally, organisations must also contend with:

• Delivery mechanisms that remain complex, particularly for in vivo applications
• Manufacturing processes that are difficult to scale
• Limited long-term safety data

For organisations investing heavily in these modalities, the risk lies in assuming that scientific feasibility means there is potential for scalable therapies.

The Translational Gap: Where Drug Discovery Still Fails

The gap between promising preclinical results and clinical success has always been the real challenge for drug discovery.

Despite improvements in modelling and early-stage testing, a significant proportion of candidates still fail in early clinical phases. This is often due to:

• Poor predictive value of preclinical models
• Incomplete understanding of disease biology
• Variability in human response

Translational science aims to bridge this gap, but progress has been limited.

Biomarkers, for example, have been positioned as a key solution, and initiatives such as the Biomarkers Consortium have advanced the development and validation of biomarkers across multiple therapeutic areas.

But, here’s the catch: Not all diseases have well-defined biomarkers, and not all biomarkers are clinically actionable. Therefore, while biomarkers can enhance decision-making, they are not a universal solution to attrition.

Data Is the Foundation

Modern drug discovery is increasingly data-driven, relying on the integration of enormous genomic, clinical, and real-world datasets.

This should lead to better insights, but it also introduces a set of new challenges:

• Data is often siloed across systems and organisations
• Standards for data quality and interoperability vary
• Regulatory considerations limit data sharing

Initiatives like the Global Alliance for Genomics and Health are trying to fix this by promoting frameworks for responsible data sharing and interoperability.

As datasets grow in size and complexity, the challenge shifts from access to interpretation. Extracting meaningful insights requires advanced tools and domain expertise.

For many biopharmaceutical organisations, the real bottleneck is no longer data generation. It is data integration and utilisation.

Image

Operational Complexity Is Often the Hidden Factor

While most of the focus is on scientific and technological innovation, operational execution often separates winners from the rest.

As discovery becomes more technologically advanced, it also becomes more complex to manage:

• Cross-functional collaboration is required between data scientists, biologists, and clinicians.
• New technologies must be integrated into existing workflows.
• External partnerships are increasingly necessary.

These operational challenges introduce risk. Misalignment between teams, delays in validation, and challenges in scaling processes can all offset the benefits of new technologies.

In this context, execution becomes a competitive differentiator. Organisations that can effectively integrate new tools into cohesive workflows are more likely to realise value from innovation.

View interview AI in Pharma: Hype vs. What Actually Works

AI in Pharma: Hype vs. What Actually Works

Expert Lara Masad explains why pharma leaders miscalculate AI investments and how to build a defensible validation strategy.

Image

Who Gains and Who Falls Behind

The shift in the discovery paradigm is not affecting all biopharmaceutical players equally.

Large pharmaceutical companies

• Have access to extensive datasets and resources
• Are investing heavily in AI and partnerships
• May struggle with organisational inertia

Biotech companies

• Often more agile and focused
• Able to adopt new technologies quickly
• Constrained by funding and scale

Technology providers

• Play an increasingly central role
• Offer specialised capabilities in AI, data, and automation
• Must demonstrate real-world impact to gain trust

This evolving landscape is creating new forms of competition and new opportunities for collaboration.

What Pharma Leaders Need to Rethink

For senior decision-makers, the current environment requires a shift in mindset.

1. From tools to systems

Investing in individual technologies is not enough. Value is created through integration across the drug discovery lifecycle.

2. From speed to predictability

Faster discovery is only meaningful if it leads to higher success rates. For drug discovery programs, efficiency must be measured in outcomes, not just timelines.

3. From data accumulation to data strategy

More data does not automatically lead to better insights. Organisations need clear strategies for data governance, integration, and use.

4. From innovation to execution

Scientific breakthroughs are necessary, but insufficient. Operational capability determines whether those breakthroughs translate into therapies.

Looking Ahead

The drug discovery process is changing rapidly with the convergence of AI, advanced biology, and data science. However, the industry is not starting from a blank slate. Legacy systems, regulatory requirements, and biological complexity continue to shape outcomes.

The next phase of pharma evolution will not be defined by new technologies so much as it will be by how effectively they are integrated into the drug discovery process.

Developing a New Pharma Paradigm

The biopharmaceutical industry is moving forward at unprecedented speed. The way forward and how to reach there is still unclear. At the same time, fundamental drug discovery challenges remain in terms of translation, validation, and execution.

A new pharma paradigm is needed to manage the integration of new technologies and rapid advances while practical realities and real limitations still exist.

Pharmatica focuses on this intersection to examine where scientific progress meets operational reality, providing the clarity needed to make better decisions in an increasingly complex pharmaceutical landscape.

Pharmatica: Insight. Connection. Impact.